BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Bayer

Status: Completed

Conditions: Secondary Progressive MS (SPMS); Relapsing Remitting MS (RRMS)

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01233245

14192

BF0704 (Other Identifier)

Details and patient eligibility

About

This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors. The patients were evaluated under normal clinical practice and were asked to fill out the quality of life FAMS questionnaire, Coping processes (WCQ - Ways of Coping Questionnaire) and depression questionnaire CES-D.

Enrollment: 1,077 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)
• Previous treatment with disease modifying drugs
• Adjustment of disease modifying treatment necessary at the discretion of the investigator
• Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion

Exclusion criteria

• Patients not fulfilling the indications in the local prescribing information
• Refusal to sign inform consent

Trial design

1,077 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)